ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

COV Cover 50 SPA

0.00
0.00 (0.00%)
Share Name Share Symbol Market Type
Cover 50 SPA BIT:COV Italy Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.00 -

Covidien Recalls Duet TRS Staplers on Anatomical Injury Potential

22/08/2012 3:10pm

Dow Jones News


Cover 50 (BIT:COV)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Cover 50 Charts.
   By Saabira Chaudhuri 
 

Covidien PLC (COV) is voluntarily recalling its Duet TRS staplers after receiving one report that links the tissue reinforcement material to a post-operative injury after abdominal surgery.

Launched in 2009, the product is a tissue reinforcement system to support staple lines. To date, Covidien has sold more than 540,000 worldwide.

Covidien on Wednesday said it has stopped manufacturing the units, after concluding that Duet TRS may have the potential to injure adjacent anatomical structures, which may result in life threatening post-operative complications.

The affected product codes range between 4535 to 6048A.

The most recent recall is in addition to one unveiled in January relating to the contraindication of the device in the thoracic cavity. At that time, Covidien received reports of 13 serious injuries and three fatalities following the application of Duet TRS in the thoracic cavity.

On Wednesday, the company said all Duet TRS products can be returned by emailing feedback.customerservice@covidien.com or calling 1-800-722-8772, option 1, to obtain a return goods authorization prior to returning the affected units.

People can report adverse events or quality problems related to the product by calling or emailing the Food and Drug Administration's MedWatch Adverse Event Reporting program.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires


1 Year Cover 50 Chart

1 Year Cover 50 Chart

1 Month Cover 50 Chart

1 Month Cover 50 Chart

Your Recent History

Delayed Upgrade Clock